|
| Demographic and clinical characteristics | Number (percentage) | Mean ± standard deviation; IQR |
|
| Gender (female) | 223/238 (93.7%) | |
| Age (years) | | 58.8 ± 10.8 (range 22–85) |
| Subcategories |
| Adults (age 22–64 years) | 159/238 (66.8%) | |
| Elderly (age ≥65 years) | 79/238 (33.2%) | |
| Duration of the disease (years) | | 15.1 ± 11.0 (range 1–55) |
| Current smoker or ex-smoker | 13/238 (5.5%) | |
| Autoantibodies |
| Rheumatoid factor | 178/238 (74.8%) | |
| Anti-CCP antibodies | 128/189 (67.7%) | |
| Anti-Ro antibodies | 19/104 (18.3%) | |
| Probable secondary Sjogren’s syndrome | 64/238 (26.9%) | |
| Dry eyes and mouth >3 months | 140/238 (58.8%) | |
| Positive Schirmer’s test (<5 mm in 5 minutes) | 50/238 (21.0%) | |
| Anti-Ro/La antibodies | 43/195 (22.1%) | |
| Disease activity |
| Swollen joint count (SJC) | | 1.4 ± 2.2 (median 1, range 0–20) |
| Tender joint count (TJC) | | 1.5 ± 2.5 (median 0, range 0–14) |
| Patient general health (PatGH) | | 3.8 ± 2.4 (median 4.0, range 0–10) |
| Physician global health (PhyGH) | | 1.1 ± 1.5 (median 0.7, range 0–8.4) |
| Clinical disease activity index (CDAI) | | 7.8 ± 6.2 (median 6.5, range 0–40.4) |
| Active disease (CDAI >2.8) | 197/238 (82.8%) | |
| Moderate and high disease activity (CDAI >10) | 67/238 (28.2%) | |
| Temporomandibular joint pain and stiffness | 25/238 (10.5%) | |
| Grip strength (mmHg) |
| Left hand | 62.5 ± 41.6 | |
| Right hand | 63.9 ± 43.0 | |
| Treatment |
| Disease modifying antirheumatic drugs | 212/238 (89.1%) | |
| Methotrexate | 151/238 (63.4%) | |
| Hydroxychloroquine | 94/238 (39.7%) | |
| Sulfasalazine | 62/238 (26.1%) | |
| Leflunomide | 30/238 (12.6%) | |
| Oral prednisolone | 26/238 (10.9%) | |
| Biologic agents | 32/238 (13.4%) | |
|
